Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease

Frontiers in Aging Neuroscience

Volumn 7, Issue JAN, 2015, Pages

  Barreto, George E ^a   Iarkov, Alexander ^b,c   Moran, Valentina Echeverria ^b,c,d  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Akt(PKB); Beta amyloid; Cotinine; Nicotine; Parkinson disease; Synucleinopathies

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; COTININE; DRUG METABOLITE; NICOTINE;

DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG SAFETY; HUMAN; MEMORY; MOTOR PERFORMANCE; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; REVIEW;

EID: 84922451587     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00340     Document Type: Review

References (161)

1. Aarsland, D., Bronnick, K., Williams-Gray, C., Weintraub, D., Marder, K., Kulisevsky, J., et al. (2010). Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 75, 1062-1069. doi: 10.1212/wnl.0b013e3181f39d0e
2. Albarracin, S. L., Stab, B., Casas, Z., Sutachan, J. J., Samudio, I., Gonzalez, J., et al. (2012). Effects of natural antioxidants in neurodegenerative disease. Nutr. Neurosci. 15, 1-9. doi: 10.1179/1476830511y.0000000028
3. Alcalay, R. N., Mejia-Santana, H., Tang, M. X., Rosado, L., Verbitsky, M., Kisselev, S., et al. (2009). Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch. Neurol. 66, 1517-1522. doi: 10.1001/archneurol.2009.267
4. Aosaki, T., Miura, M., Suzuki, T., Nishimura, K., and Masuda, M. (2010). Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatr. Gerontol. Int. 10(Suppl. 1), S148-S157. doi: 10.1111/j.1447-0594.2010.00588.x
5. Balakumar, P., and Kaur, J. (2009). Is nicotine a key player or spectator in the induction and progression of cardiovascular disorders? Pharmacol. Res. 60, 361-368. doi: 10.1016/j.phrs.2009.06.005
6. Baron, J. A. (1996). Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. Br. Med. Bull. 52, 58-73. doi: 10.1093/oxfordjournals.bmb.a011533
7. Barreto, G. E., Capanes, F., and Cabezas, R. (2014a). Cortical spreading depression and mitochondrial dysfunction with aging: lessons from ethanol abuse. Front. Aging Neurosci. 6:117. doi: 10.3389/fnagi.2014.00117
8. Barreto, G. E., Gonzalez, J., Torres, Y., and Morales, L. (2011). Astrocytic-neuronal crosstalk: implications for neuroprotection from brain injury. Neurosci. Res. 71, 107-113. doi: 10.1016/j.neures.2011.06.004
9. Barreto, G., Madureira, D., Capani, F., Aon-Bertolino, L., Saraceno, E., and Alvarez-Giraldez, L. D. (2009). The role of catechols and free radicals in benzene toxicity: an oxidative DNA damage pathway. Environ. Mol. Mutagen. 50, 771-780. doi: 10.1002/em.20500
10. Barreto, G. E., Santos-Galindo, M., and Garcia-Segura, L. M. (2014b). Selective estrogen receptor modulators regulate reactive microglia after penetrating brain injury. Front. Aging Neurosci. 6:132. doi: 10.3389/fnagi.2014.00132
11. Barreto, G. E., Veiga, S., Azcoitia, I., garcia-Segura, L. M., and Garcia-Ovejero, D. (2007). Testosterone decreases reactive astroglia and reactive microglia after brain injury in male rats: role of its metabolites, oestradiol and dihydrotestosterone. Eur. J. Neurosci. 25, 3039-3046. doi: 10.1111/j.1460-9568.2007.05563.x
12. Bar-Shira, A., Gana-Weisz, M., Gan-Or, Z., Giladi, E., Giladi, N., and Orr-Urtreger, A. (2014). CHRNB3 c.-57A>G functional promoter change affects Parkinson's disease and smoking. Neurobiol. Aging 35, 2179.e1-2179.e6. doi: 10.1016/j.neurobiolaging.2014.03.014
13. Baykan, A., Narin, N., Narin, F., Akgün, H., Yavascan, S., and Saraymen, R. (2008). The protective effect of melatonin on nicotine-induced myocardial injury in newborn rats whose mothers received nicotine. Anadolu Kardiyol Derg 8, 243-248.
14. Benowitz, N. L., Dains, K. M., Dempsey, D., Wilson, M., and Jacob, P. (2011). Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure. Nicotine Tob. Res. 13, 772-783. doi: 10.1093/ntr/ntr072
15. Benowitz, N. L., and Gourlay, S. G. (1997). Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J. Am. Coll. Cardiol. 29, 1422-1431. doi: 10.1016/s0735-1097(97)00079-x
16. Benowitz, N. L., Hansson, A., and Jacob, P. (2002). Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension 39, 1107-1112. doi: 10.1161/01.hyp.0000018825.76673.ea
17. Benowitz, N. L., Hukkanen, J., and Jacob, P. (2009). Nicotine chemistry, metabolism, kinetics and biomarkers. Handb. Exp. Pharmacol. 192, 29-60. doi: 10.1007/978-3-540-69248-5_2
18. Benowitz, N. L., and Jacob, P. (1993). Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin. Pharmacol. Ther. 53, 316-323. doi: 10.1038/clpt.1993.27
19. Benowitz, N. L., and Jacob, P. (1994). Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin. Pharmacol. Ther. 56, 483-493. doi: 10.1038/clpt.1994.169
20. Benowitz, N. L., and Jacob, P. (1997). Individual differences in nicotine kinetics and metabolism in humans. NIDA Res. Monogr. 173, 48-64.
21. Benowitz, N. L., Jacob, P., Fong, I., and Gupta, S. (1994). Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J. Pharmacol. Exp. Ther. 268, 296-303.
22. Benowitz, N. L., Jacob, P., and Perez-Stable, E. (1996). CYP2D6 phenotype and the metabolism of nicotine and cotinine. Pharmacogenetics 6, 239-242. doi: 10.1097/00008571-199606000-00006
23. Bergen, A. W., and Caporaso, N. (1999). Cigarette smoking. J. Natl. Cancer Inst. 91, 1365-1375.
24. Bordia, T., McGregor, M., Papke, R. L., Decker, M. W., Michael McIntosh, J., and Quik, M. (2014). The a7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. Exp. Neurol. doi: 10.1016/j.expneurol.2014.09.015. [Epub ahead of print].
25. Bové, J., and Perier, C. (2012). Neurotoxin-based models of Parkinson's disease. Neuroscience 211, 51-76. doi: 10.1016/j.neuroscience.2011.10.057
26. Briggs, C. A., Anderson, D. J., Brioni, J. D., Buccafusco, J. J., Buckley, M. J., Campbell, J. E., et al. (1997). Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav. 57, 231-241. doi: 10.1016/s0091-3057(96)00354-1
27. Briggs, C. A., McKenna, D. G., and Piattoni-Kaplan, M. (1995). Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacology 34, 583-590. doi: 10.1016/0028-3908(95)00028-5
28. Buccafusco, J. J., and Terry, A. V. Jr. (2003). The potential role of cotinine in the cognitive and neuroprotective actions of nicotine. Life Sci. 72, 2931-2942. doi: 10.1016/s0024-3205(03)00226-1
29. Buccafusco, J. J., and Terry, A. V. Jr. (2009). A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem. Pharmacol. 78, 852-862. doi: 10.1016/j.bcp.2009.06.102
30. Budzianowski, J. (2013). Tobacco-once a medicinal plant. Does it contain substances with medicinal properties?. Przegl. Lek. 70, 865-868.
31. Büeler, H. (2010). Mitochondrial dynamics, cell death and the pathogenesis of Parkinson's disease. Apoptosis 15, 1336-1353. doi: 10.1007/s10495-010-0465-0
32. Burgess, S., Zeitlin, R., Gamble-George, J., and Echeverria Moran, V. (2012). Cotinine is neuroprotective against beta-amyloid toxicity. J. Clin. Toxicol. S6, 001-003. doi: 10.4172/2161-0495.S6-003
33. Burghaus, L., Schütz, U., Krempel, U., Lindstrom, J., and Schröder, H. (2003). Loss of nicotinic acetylcholine receptor subunits alpha4 and alpha7 in the cerebral cortex of Parkinson patients. Parkinsonism Relat. Disord. 9, 243-246. doi: 10.1016/s1353-8020(03)00028-2
34. Cabezas, R., Avila, M., Gonzalez, J., El-Bachá, R. S., Báez, E., García-Segura, L. M., et al. (2014). Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease". Front. Cell. Neurosci. 8:211. doi: 10.3389/fncel.2014.00211
35. Cabezas, R., El-Bachá, R. S., González, J., and Barreto, G. E. (2012). Mitochondrial functions in astrocytes: neuroprotective implications from oxidative damage by rotenone. Neurosci. Res. 74, 80-90. doi: 10.1016/j.neures.2012.07.008
36. Caldwell, B., Sumner, W., and Crane, J. (2012). A systematic review of nicotine by inhalation: is there a role for the inhaled route? Nicotine Tob. Res. 14, 1127-1139. doi: 10.1093/ntr/nts009
37. Camilleri, A., and Vassallo, N. (2014). The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease. CNS Neurosci. Ther. 20, 591-602. doi: 10.1111/cns.12264
38. Carnevale, D., De Simone, R., and Minghetti, L. (2007). Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol. Disord. Drug Targets 6, 388-397. doi: 10.2174/187152707783399193
39. Cashman, J. R., Park, S. B., Yang, Z. C., Wrighton, S. A., Jacob, P., and Benowitz, N. L. (1992). Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide. Chem. Res. Toxicol. 5, 639-646. doi: 10.1021/tx00029a008
40. Celardo, I., Martins, L. M., and Gandhi, S. (2014). Unravelling mitochondrial pathways to Parkinson's disease. Br. J. Pharmacol. 171, 1943-1957. doi: 10.1111/bph.12433
41. Chen, H., Huang, X., Guo, X., Mailman, R., Park, B. Y., Kamel, F., et al. (2010). Smoking duration, intensity and risk of Parkinson disease. Neurology 74, 878-884. doi: 10.1212/WNL.0b013e3181d55f38
42. Connolly, B. S., and Lang, A. E. (2014). Pharmacological treatment of Parkinson disease: a review. JAMA 311, 1670-1683. doi: 10.1001/jama.2014.3654
43. Conte, A., Khan, N., Defazio, G., Rothwell, J. C., and Berardelli, A. (2013). Pathophysiology of somatosensory abnormalities in Parkinson disease. Nat. Rev. Neurol. 9, 687-697. doi: 10.1038/nrneurol.2013.224
44. Corti, O., Lesage, S., and Brice, A. (2011). What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol. Rev. 91, 1161-1218. doi: 10.1152/physrev.00022.2010
45. Costa, G., Abin-Carriquiry, J. A., and Dajas, F. (2001). Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res. 888, 336-342. doi: 10.1016/s0006-8993(00)03087-0
46. Cummings, J. L. (1988a). The dementias of Parkinson's disease: prevalence, characteristics, neurobiology and comparison with dementia of the Alzheimer type. Eur. Neurol. 28(Suppl. 1), 15-23.
47. Cummings, J. L. (1988b). Intellectual impairment in Parkinson's disease: clinical, pathologic and biochemical correlates. J. Geriatr. Psychiatry Neurol. 1, 24-36. doi: 10.1177/089198878800100106
48. Dasgupta, P., and Chellappan, S. P. (2006). Nicotine-mediated cell proliferation and angiogenesis: new twists to an old story. Cell Cycle 5, 2324-2328. doi: 10.4161/cc.5.20.3366
49. Davis, S. J., Lyzogubov, V. V., Tytarenko, R. G., Safar, A. N., Bora, N. S., and Bora, P. S. (2012). The effect of nicotine on anti-vascular endothelial growth factor therapy in a mouse model of neovascular age-related macular degeneration. Retina 32, 1171-1180. doi: 10.1097/IAE.0b013e31823496b8
50. Dempsey, D., Jacob, P. 3rd, and Benowitz, N. L. (2000). Nicotine metabolism and elimination kinetics in newborns. Clin. Pharmacol. Ther. 67, 458-465. doi: 10.1067/mcp.2000.106129
51. Dempsey, D. A., Sambol, N. C., Jacob, P., Hoffmann, E., Tyndale, R. F., Fuentes-Afflick, E., et al. (2013). CYP2A6 genotype but not age determines cotinine half-life in infants and children. Clin. Pharmacol. Ther. 94, 400-406. doi: 10.1038/clpt.2013.114
52. De Reuck, J., De Weweire, M., Van Maele, G., and Santens, P. (2005). Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease. J. Neurol. Sci. 231, 35-39. doi: 10.1016/j.jns.2004.12.003
53. Derkinderen, P., Shannon, K. M., and Brundin, P. (2014). Gut feelings about smoking and coffee in Parkinson's disease. Mov. Disord. 29, 976-979. doi: 10.1002/mds.25882
54. Dexter, D. T., and Jenner, P. (2013). Parkinson disease: from pathology to molecular disease mechanisms. Free Radic. Biol. Med. 62, 132-144. doi: 10.1016/j.freeradbiomed.2013.01.018
55. Díaz, A., De Jesús, L., Mendieta, M., Calvillo, B., Espinosa, E., Zenteno, J., et al. (2010). The amyloid-beta25-35 injection into the CA1 region of the neonatal rat hippocampus impairs the long-term memory because of an increase of nitric oxide. Neurosci. Lett. 468, 151-155. doi: 10.1016/j.neulet.2009.10.087
56. Dos Santos, A. B., Barreto, G. E., and Kohlmeier, K. A. (2014). Treatment of sleeping disorders should be considered in clinical management of Parkinson's disease. Front. Aging Neurosci. 6:273. doi: 10.3389/fnagi.2014.00273
57. Dwoskin, L. P., Teng, L., Buxton, S. T., and Crooks, P. A. (1999). (S)-(-)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. J. Pharmacol. Exp. Ther. 288, 905-911.
58. Echeverria, V., and Zeitlin, R. (2012). Cotinine: a potential new therapeutic agent against Alzheimer's disease. CNS Neurosci. Ther. 18, 517-523. doi: 10.1111/j.1755-5949.2012.00317.x
59. Echeverria, V., Zeitlin, R., Burgess, S., Patel, S., Barman, A., Thakur, G., et al. (2011). Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer's disease mice. J. Alzheimers Dis. 24, 817-835. doi: 10.3233/JAD-2011-102136
60. Edison, P., Ahmed, I., Fan, Z., Hinz, R., Gelosa, G., Ray Chaudhuri, K., et al. (2013). Microglia, amyloid and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology 38, 938-949. doi: 10.1038/npp.2012.255
61. El-Agnaf, O. M., and Irvine, G. B. (2002). Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem. Soc. Trans. 30, 559-565. doi: 10.1042/bst0300559
62. Faucheux, B. A., Martin, M. E., Beaumont, C., Hauw, J. J., Agid, Y., and Hirsch, E. C. (2003). Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease. J. Neurochem. 86, 1142-1148. doi: 10.1046/j.1471-4159.2003.01923.x
63. Fujii, Y. X., Fujigaya, H., Moriwaki, Y., Misawa, H., Kasahara, T., Grando, S. A., et al. (2007). Enhanced serum antigen-specific IgG1 and proinflammatory cytokine production in nicotinic acetylcholine receptor alpha7 subunit gene knockout mice. J. Neuroimmunol. 189, 69-74. doi: 10.1016/j.jneuroim.2007.07.003
64. Gahring, L. C., and Rogers, S. W. (2005). Neuronal nicotinic acetylcholine receptor expression and function on nonneuronal cells. AAPS J. 7, E885-E894. doi: 10.1208/aapsj070486
65. Garrido-Gil, P., Rodriguez-Pallares, J., Dominguez-Meijide, A., Guerra, M. J., and Labandeira-Garcia, J. L. (2013). Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells. Exp. Neurol. 250, 384-396. doi: 10.1016/j.expneurol.2013.10.013
66. Graham, A. J., Martin-Ruiz, C. M., Teaktong, T., Ray, M. A., and Court, J. A. (2002). Human brain nicotinic receptors, their distribution and participation in neuropsychiatric disorders. Curr. Drug Targets CNS Neurol. Disord. 1, 387-397. doi: 10.2174/1568007023339283
67. Grizzell, J. A., Iarkov, A., Holmes, R., Mori, T., and Echeverria, V. (2014). Cotinine reduces depressive-like behavior, working memory deficits and synaptic loss associated with chronic stress in mice. Behav. Brain Res. 268, 55-65. doi: 10.1016/j.bbr.2014.03.047
68. Guan, Y. Z., Jin, X. D., Guan, L. X., Yan, H. C., Wang, P., Gong, Z., et al. (2014). Nicotine inhibits microglial proliferation and is neuroprotective in global ischemia rats. Mol. Neurobiol. doi: 10.1007/s12035-014-8825-3. [Epub ahead of print].
69. Gupta, H., and Babu, R. J. (2013). Transdermal delivery: product and patent update. Recent Patents Drug Deliv. Formul. 7, 184-205. doi: 10.2174/187221130703131128121747
70. Havekes, R., Abel, T., and Van der Zee, E. A. (2011). The cholinergic system and neostriatal memory functions. Behav. Brain Res. 221, 412-423. doi: 10.1016/j.bbr.2010.11.047
71. Hecht, S. S., Spratt, T. E., and Trushin, N. (2000). Absolute configuration of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol formed metabolically from 4-(methylnitrosamino) -1-(3-pyridyl)-1-butanone. Carcinogenesis 21:850. doi: 10.1093/oxfordjournals.carcin.a013781
72. Heitzer, T., Ylä Herttuala, S., Wild, E., Luoma, J., and Drexler, H. (1999). Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. J. Am. Coll. Cardiol. 33, 499-505. doi: 10.1016/s0735-1097(98)00584-1
73. Helen, A., Rajasree, C. R., Krishnakumar, K., Augusti, K. T., and Vijayammal, P. L. (1999). Antioxidant role of oils isolated from garlic (Allium sativum Linn) and onion (Allium cepa Linn) on nicotine-induced lipid peroxidation. Vet. Hum. Toxicol. 41, 316-319.
74. Hernán, M. A., Takkouche, B., Caamaño-Isorna, F., and Gestal-Otero, J. J. (2002). A meta-analysis of coffee drinking, cigarette smoking and the risk of Parkinson's disease. Ann. Neurol. 52, 276-284. doi: 10.1002/ana.10277
75. Hirsch, E. C., Breidert, T., Rousselet, E., Hunot, S., Hartmann, A., and Michel, P. P. (2003a). The role of glial reaction and inflammation in Parkinson's disease. Ann. N Y Acad. Sci. 991, 214-228. doi: 10.1111/j.1749-6632.2003.tb07478.x
76. Hirsch, E. C., Orieux, G., Muriel, M. P., Francois, C., and Feger, J. (2003b). Nondopaminergic neurons in Parkinson's disease. Adv. Neurol. 91, 29-37.
77. Hong, D. P., Fink, A. L., and Uversky, V. N. (2009). Smoking and Parkinson's disease: does nicotine affect alpha-synuclein fibrillation? Biochim. Biophys. Acta 1794, 282-290. doi: 10.1016/j.bbapap.2008.09.026
78. Hu, M. T., Szewczyk-Królikowski, K., Tomlinson, P., Nithi, K., Rolinski, M., Murray, C., et al. (2014). Predictors of cognitive impairment in an early stage Parkinson's disease cohort. Mov. Disord. 29, 351-359. doi: 10.1002/mds.25748
79. Hughes, T. A., Ross, H. F., Musa, S., Bhattacherjee, S., Nathan, R. N., Mindham, R. H., et al. (2000). A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 54, 1596-1602. doi: 10.1212/wnl.54.8.1596
80. Jellinger, K. A. (2003). Prevalence of Alzheimer lesions in Parkinson's disease. Mov. Disord. 18, 1207-1208. doi: 10.1002/mds.10513
81. Kalaitzakis, M. E., Graeber, M. B., Gentleman, S. M., and Pearce, R. K. (2008). Striatal ß-amyloid deposition in Parkinson disease with dementia. J. Neuropathol. Exp. Neurol. 67, 155-161. doi: 10.1097/NEN.0b013e31816362aa
82. Kalra, R., Singh, S. P., Kracko, D., Matta, S. G., Sharp, B. M., and Sopori, M. L. (2002). Chronic self-administration of nicotine in rats impairs T cell responsiveness. J. Pharmacol. Exp. Ther. 302, 935-939. doi: 10.1124/jpet.302.3.935
83. Kalra, R., Singh, S. P., Pena-Philippides, J. C., Langley, R. J., Razani-Boroujerdi, S., and Sopori, M. L. (2004). Immunosuppressive and anti-inflammatory effects of nicotine administered by patch in an animal model. Clin. Diagn. Lab. Immunol. 11, 563-568. doi: 10.1128/cdli.11.3.563-568.2004
84. Kawamata, J., and Shimohama, S. (2011). Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases. J. Alzheimers Dis. 24(Suppl. 2), 95-109. doi: 10.3233/JAD-2011-110173
85. Kelton, M. C., Kahn, H. J., Conrath, C. L., and Newhouse, P. A. (2000). The effects of nicotine on Parkinson's disease. Brain Cogn. 43, 274-282.
86. Kem, W. R. (2000). The brain a7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav. Brain Res. 113, 169-181. doi: 10.1016/s0166-4328(00)00211-4
87. Kem, W. R., Mahnir, V. M., Papke, R. L., and Lingle, C. J. (1997). Anabaseine is a potent agonist on muscle and neuronal alpha-bungarotoxin-sensitive nicotinic receptors. J. Pharmacol. Exp. Ther. 283, 979-992.
88. Klein, A. M., and Ferrante, R. J. (2007). The neuroprotective role of creatine. Subcell. Biochem. 46, 205-243. doi: 10.1007/978-1-4020-6486-9_11
89. Kurosinski, P., Guggisberg, M., and Götz, J. (2002). Alzheimer's and Parkinson's disease-overlapping or synergistic pathologies? Trends Mol. Med. 8, 3-5. doi: 10.1016/s1471-4914(01)02246-8
90. Labandeira-García, J. L., Garrido-Gil, P., Rodriguez-Pallares, J., Valenzuela, R., Borrajo, A., and Rodríguez-Perez, A. I. (2014). Brain renin-angiotensin system and dopaminergic cell vulnerability. Front. Neuroanat. 8:67. doi: 10.3389/fnana.2014.00067
91. Liu, J. H., Li, X. S., Ye, J., Gao, L. H., Zhang, Z. P., Wu, W., et al. (2012). Cognitive impairments in Parkinson's disease. Aging Ment. Health 16, 529-536. doi: 10.1080/13607863.2011.628979
92. Lorenz, R., Samnick, S., Dillmann, U., Schiller, M., Ong, M. F., Faßbender, K., et al. (2014). Nicotinic a4ß2 acetylcholine receptors and cognitive function in Parkinson's disease. Acta Neurol. Scand. 130, 164-171. doi: 10.1111/ane.12259
93. Luetje, C. W., Patrick, J., and Séguéla, P. (1990). Nicotine receptors in the mammalian brain. Faseb J. 4, 2753-2760.
94. Maggio, R., Riva, M., Vaglini, F., Fornai, F., Racagni, G., and Corsini, G. U. (1997). Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism. J. Neural Transm. 104, 1113-1123. doi: 10.1007/bf01273324
95. Mandal, P. K., Pettegrew, J. W., Masliah, E., Hamilton, R. L., and Mandal, R. (2006). Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem. Res. 31, 1153-1162. doi: 10.1007/s11064-006-9140-9
96. McGeer, P. L., and McGeer, E. G. (2004). Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord. 10(Suppl. 1), S3-S7. doi: 10.1016/j.parkreldis.2004.01.005
97. McKay, B. E., Placzek, A. N., and Dani, J. A. (2007). Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors. Biochem. Pharmacol. 74, 1120-1133. doi: 10.1016/j.bcp.2007.07.001
98. McKennis, H. Jr., Turnbull, L. B., and Bowman, E. R. (1963). N-Methylation of nicotine ad cotinine in vivo. J. Biol. Chem. 238, 719-723.
99. Mellick, G. D., Gartner, C. E., Silburn, P. A., and Battistutta, D. (2006). Passive smoking and Parkinson disease. Neurology 67, 179-180. doi: 10.1212/01.wnl.0000223618.53129.56
100. Meredith, G. E., Totterdell, S., Potashkin, J. A., and Surmeier, D. J. (2008). Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord. 14(Suppl. 2), S112-S115. doi: 10.1016/j.parkreldis.2008.04.012
101. Molander, L., Hansson, A., and Lunell, E. (2001). Pharmacokinetics of nicotine in healthy elderly people. Clin. Pharmacol. Ther. 69, 57-65. doi: 10.1067/mcp.2001.113181
102. Moran, V. E. (2012). Cotinine: beyond that expected, more than a biomarker of tobacco consumption. Front. Pharmacol. 3:173. doi: 10.3389/fphar.2012.00173
103. Murer, M. G., and Moratalla, R. (2011). Striatal signaling in L-dopa-induced dyskinesia: common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation. Front. Neuroanat. 5:51. doi: 10.3389/fnana.2011.00051
104. Neurath, G. B. (1994). Aspects of the oxidative metabolism of nicotine. Clin. Investig. 72, 190-195. doi: 10.1007/bf00189309
105. Nordberg, A. (1994). Human nicotinic receptors-their role in aging and dementia. Neurochem. Int. 25, 93-97. doi: 10.1016/0197-0186(94)90059-0
106. Nunomura, A., Moreira, P. I., Lee, H. G., Zhu, X., Castellani, R. J., Smith, M. A., et al. (2007). Neuronal death and survival under oxidative stress in Alzheimer and Parkinson diseases. CNS Neurol. Disord. Drug Targets 6, 411-423. doi: 10.2174/187152707783399201
107. O'Leary, K., Parameswaran, N., McIntosh, J. M., and Quik, M. (2008). Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum. J. Pharmacol. Exp. Ther. 325, 646-654. doi: 10.1124/jpet.108.136838
108. O'Reilly, E. J., Chen, H., Gardener, H., Gao, X., Schwarzschild, M. A., and Ascherio, A. (2009). Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality. Am. J. Epidemiol. 169, 678-682. doi: 10.1093/aje/kwn388
109. Palazzolo, D. L. (2013). Electronic cigarettes and vaping: a new challenge in clinical medicine and public health. A literature review. Front. Public Health 1:56. doi: 10.3389/fpubh.2013.00056
110. Parain, K., Hapdey, C., Rousselet, E., Marchand, V., Dumery, B., and Hirsch, E. C. (2003). Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res. 984, 224-232. doi: 10.1016/s0006-8993(03)03195-0
111. Perez, V. P., de Lima, M. N., da Silva, R. S., Dornelles, A. S., Vedana, G., Bogo, M. R., et al. (2010). Iron leads to memory impairment that is associated with a decrease in acetylcholinesterase pathways. Curr. Neurovasc. Res. 7, 15-22. doi: 10.2174/156720210790820172
112. Perez, X. A., Ly, J., McIntosh, J. M., and Quik, M. (2012). Long-term nicotine exposure depresses dopamine release in nonhuman primate nucleus accumbens. J. Pharmacol. Exp. Ther. 342, 335-344. doi: 10.1124/jpet.112.194084
113. Perez, X. A., McIntosh, J. M., and Quik, M. (2013). Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens. J. Neurochem. 127, 762-771. doi: 10.1111/jnc.12442
114. Perfeito, R., Cunha-Oliveira, T., and Rego, A. C. (2013). Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. Free Radic. Biol. Med. 62, 186-201. doi: 10.1016/j.freeradbiomed.2013.05.042
115. Perier, C., and Vila, M. (2012). Mitochondrial biology and Parkinson's disease. Cold Spring Harb. Perspect. Med. 2:a009332. doi: 10.1101/cshperspect.a009332
116. Pillai, S., and Chellappan, S. (2012). a7 nicotinic acetylcholine receptor subunit in angiogenesis and epithelial to mesenchymal transition. Curr. Drug Targets 13, 671-679. doi: 10.2174/138945012800398847
117. Quik, M., Bordia, T., Huang, L., and Perez, X. (2011a). Targeting nicotinic receptors for Parkinson's disease therapy. CNS Neurol. Disord. Drug Targets 10, 651-658. doi: 10.2174/187152711797247849
118. Quik, M., Chen, L., Parameswaran, N., Xie, X., Langston, J. W., and McCallum, S. E. (2006a). Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. J. Neurosci. 26, 4681-4689. doi: 10.1523/jneurosci.0215-06.2006
119. Quik, M., Parameswaran, N., McCallum, S. E., Bordia, T., Bao, S. A., McCormack, A., et al. (2006b). Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J. Neurochem. 98, 1866-1875. doi: 10.1111/j.1471-4159.2006.04078.x
120. Quik, M., Park, K. M., Hrachova, M., Mallela, A., Huang, L. Z., McIntosh, J. M., et al. (2012a). Role for a6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice. Neuropharmacology 63, 450-459. doi: 10.1016/j.neuropharm.2012.04.029
121. Quik, M., Perez, X. A., and Bordia, T. (2012b). Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov. Disord. 27, 947-957. doi: 10.1002/mds.25028
122. Quik, M., Perez, X. A., and Grady, S. R. (2011b). Role of a6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders. Biochem. Pharmacol. 82, 873-882. doi: 10.1016/j.bcp.2011.06.001
123. Quik, M., and Wonnacott, S. (2011c). α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol. Rev. 63, 938-966. doi: 10.1124/pr.110.003269
124. Rehani, K., Scott, D. A., Renaud, D., Hamza, H., Williams, L. R., Wang, H., et al. (2008). Cotinine-induced convergence of the cholinergic and PI3 kinase-dependent anti-inflammatory pathways in innate immune cells. Biochim. Biophys. Acta 1783, 375-382. doi: 10.1016/j.bbamcr.2007.12.003
125. Riedel, O., Klotsche, J., and Wittchen, H. U. (2014). Motor impairment, depression, dementia: which forms the impression of disease severity in Parkinson's disease? Parkinsonism Relat. Disord. 20, 1365-1370. doi: 10.1016/j.parkreldis.2014.09.025
126. Ritz, B., Lee, P. C., Lassen, C. F., and Arah, O. A. (2014). Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease. Neurology 83, 1396-1402. doi: 10.1212/WNL.0000000000000879
127. Rodella, L. F., Rossini, C., Favero, G., Foglio, E., Loreto, C., and Rezzani, R. (2012). Nicotine-induced morphological changes in rat aorta: the protective role of melatonin. Cells Tissues Organs 195, 252-259. doi: 10.1159/000324919
128. Roth, J. A. (2014). Correlation between the biochemical pathways altered by mutated parkinson-related genes and chronic exposure to manganese. Neurotoxicology 44C, 314-325. doi: 10.1016/j.neuro.2014.08.006
129. Rottschy, C., Kleiman, A., Dogan, I., Langner, R., Mirzazade, S., Kronenbuerger, M., et al. (2013). Diminished activation of motor working-memory networks in Parkinson's disease. PLoS One 8:e61786. doi: 10.1371/journal.pone.0061786
130. Sanford, Z., and Goebel, L. (2014). E-cigarettes: an up to date review and discussion of the controversy. W. V. Med. J. 110, 10-15.
131. Sasaki, M., Ichiya, Y., Hosokawa, S., Otsuka, M., Kuwabara, Y., Fukumura, T., et al. (1992). Regional cerebral glucose metabolism in patients with Parkinson's disease with or without dementia. Ann. Nucl. Med. 6, 241-246. doi: 10.1007/bf03164661
132. Schmid, A. W., Fauvet, B., Moniatte, M., and Lashuel, H. A. (2013). Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies. Mol. Cell. Proteomics 12, 3543-3558. doi: 10.1074/mcp. R113.032730
133. Schneider, N. G., Olmstead, R. E., Franzon, M. A., and Lunell, E. (2001). The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin. Pharmacokinet. 40, 661-684. doi: 10.2165/00003088-200140090-00003
134. Shi, C., Yu, R., Shao, S., and Li, Y. (2013). Partial activation of a7 nicotinic acetylcholine receptors: insights from molecular dynamics simulations. J. Mol. Model. 19, 871-878. doi: 10.1007/s00894-012-1618-6
135. Shin, J., Choi, S., Lee, J. E., Lee, H. S., Sohn, Y. H., and Lee, P. H. (2012). Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson's disease patients according to cognitive status. J. Neurol. Neurosurg Psychiatry 83, 315-321. doi: 10.1136/jnnp-2011-300872
136. Simuni, T., and Sethi, K. (2008). Nonmotor manifestations of Parkinson's disease. Ann. Neurol. 64(Suppl. 2), S65-S80. doi: 10.1002/ana.21472
137. Slawek, J., Wieczorek, D., Derejko, M., Dubaniewicz, M., Brockhuis, B., Sitek, E., et al. (2008). The influence of vascular risk factors and white matter hyperintensities on the degree of cognitive impairment in Parkinson's disease. Neurol. Neurochir. Pol. 42, 505-512.
138. Srivastava, E. D., Hallett, M. B., and Rhodes, J. (1989). Effect of nicotine and cotinine on the production of oxygen free radicals by neutrophils in smokers and non-smokers. Hum. Toxicol. 8, 461-463. doi: 10.1177/096032718900800605
139. Stewart, T., Liu, C., Ginghina, C., Cain, K. C., Auinger, P., Cholerton, B., et al. (2014). Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. Am. J. Pathol. 184, 966-975. doi: 10.1016/j.ajpath.2013.12.007
140. Sutachan, J. J., Casas, Z., Albarracin, S. L., Stab, B. R. 2nd, Samudio, I., Gonzalez, J., et al. (2012). Cellular and molecular mechanisms of antioxidants in Parkinson's disease. Nutr. Neurosci. 15, 120-126. doi: 10.1179/1476830511Y.0000000033
141. Suzuki, S., Kawamata, J., Matsushita, T., Matsumura, A., Hisahara, S., Takata, K., et al. (2013). 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride protects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through alpha7 nicotinic acetylcholine receptor stimulation in rats. J. Neurosci. Res. 91, 462-471. doi: 10.1002/jnr.23160
142. Tansey, M. G., and Goldberg, M. S. (2010). Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. 37, 510-518. doi: 10.1016/j.nbd.2009.11.004
143. Tatton, W. G., Chalmers-Redman, R., Brown, D., and Tatton, N. (2003). Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann. Neurol. 53(Suppl. 3), S61-S70; discussion S70-S72. doi: 10.1002/ana.10489
144. Tavassoly, O., Kakish, J., Nokhrin, S., Dmitriev, O., and Lee, J. S. (2014). The use of nanopore analysis for discovering drugs which bind to a-synuclein for treatment of Parkinson's disease. Eur. J. Med. Chem. 88, 42-54. doi: 10.1016/j.ejmech.2014.07.090
145. Terry, A. V., Buccafusco, J. J., Schade, R. F., Vandenhuerk, L., Callahan, P. M., Beck, W. D., et al. (2012). The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats. Biochem. Pharmacol. 83, 941-951. doi: 10.1016/j.bcp.2011.12.043
146. Thiriez, C., Villafane, G., Grapin, F., Fenelon, G., Remy, P., and Cesaro, P. (2011). Can nicotine be used medicinally in Parkinson's disease? Expert Rev. Clin. Pharmacol. 4, 429-436. doi: 10.1586/ecp.11.27
147. Thompson, L., Barraud, P., Andersson, E., Kirik, D., and Bjorklund, A. (2005). Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression and efferent projections. J. Neurosci. 25, 6467-6477. doi: 10.1523/jneurosci.1676-05.2005
148. Tiwari, M. N., Agarwal, S., Bhatnagar, P., Singhal, N. K., Tiwari, S. K., Kumar, P., et al. (2013). Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism. Free Radic. Biol. Med. 65, 704-718. doi: 10.1016/j.freeradbiomed.2013.07.042
149. Torrente, D., Cabezas, R., Avila, M. F., García-Segura, L. M., Barreto, G. E., and Guedes, R. C. (2014). Cortical spreading depression in traumatic brain injuries: is there a role for astrocytes?. Neurosci. Lett. 565, 2-6. doi: 10.1016/j.neulet.2013.12.058
150. Trinh, J., and Farrer, M. (2013). Advances in the genetics of Parkinson disease. Nat. Rev. Neurol. 9, 445-454. doi: 10.1038/nrneurol.2013.132
151. Whitehouse, P. J., Martino, A. M., Wagster, M. V., Price, D. L., Mayeux, R., Atack, J. R., et al. (1988). Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: an autoradiographic study. Neurology 38, 720-723. doi: 10.1212/wnl.38.5.720
152. Wirths, O., and Bayer, T. A. (2003). Alpha-synuclein, Abeta and Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 103-108. doi: 10.1016/S0278-5846(02)00339-1
153. Wright, J. W., and Harding, J. W. (2012). Importance of the brain Angiotensin system in Parkinson's disease. Parkinsons Dis. 2012:860923. doi: 10.1155/2012/860923
154. Wyss-Coray, T., and Mucke, L. (2002). Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35, 419-432. doi: 10.1016/s0896-6273(02)00794-8
155. Yanagida, T., Takeuchi, H., Kitamura, Y., Takata, K., Minamino, H., Shibaike, T., et al. (2008). Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model. Neurosci. Res. 62, 254-261. doi: 10.1016/j.neures.2008.09.003
156. Yu, J., Huang, N. F., Wilson, K. D., Velotta, J. B., Huang, M., Li, Z., et al. (2009). nAChRs mediate human embryonic stem cell-derived endothelial cells: proliferation, apoptosis and angiogenesis. PLoS One 4:e7040. doi: 10.1371/journal.pone.0007040
157. Zeng, H., Zhang, Y., Peng, L., Shao, H., Menon, N. K., Yang, J., et al. (2001). Nicotine and amyloid formation. Biol. Psychiatry 49, 248-257. doi: 10.1016/s0006-3223(00)01111-2
158. Zhang, D., Bordia, T., McGregor, M., McIntosh, J. M., Decker, M. W., and Quik, M. (2014). ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease. Mov. Disord. 29, 508-517. doi: 10.1002/mds.25817
159. Zhou, F. M., Wilson, C., and Dani, J. A. (2003). Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 9, 23-36. doi: 10.1177/1073858402239588
160. Zokaei, N., McNeill, A., Proukakis, C., Beavan, M., Jarman, P., Korlipara, P., et al. (2014). Visual short-term memory deficits associated with GBA mutation and Parkinson's disease. Brain 137, 2303-2311. doi: 10.1093/brain/awu143
161. Zuo, L., and Motherwell, M. S. (2013). The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Gene 532, 18-23. doi: 10.1016/j.gene.2013.07.085